Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation

Journal of Medical Virology

Volumn 83, Issue 3, 2011, Pages 490-495

  Halfon, Philippe ^a   Berger, Pierre ^b   Khiri, Hacene ^a   Martineau, Agnès ^a   Pénaranda, Guillaume ^a   Merlin, Michèle ^b   Faucher, Catherine ^b  

^a Hospital Ambroise Pare   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Cytomegalovirus; Plasma real time PCR; Preemptive therapy

Indexed keywords

ANTIGEN; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ADULT; ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOASSAY; KINETICS; MAJOR CLINICAL STUDY; MALE; MONITORING; NONHUMAN; OUTCOME ASSESSMENT; PREEMPTIVE THERAPY; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ALGORITHMS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KINETICS; MALE; PHOSPHOPROTEINS; PROSPECTIVE STUDIES; VIRAL LOAD; VIRAL MATRIX PROTEINS;

CYTOMEGALOVIRUS;

EID: 78851469920     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21996     Document Type: Article

References (36)

1. Abbate I, Finnstrom N, Zaniratti S, Solmone MC, Selvaggini S, Bennici E, Neri S, Brega C, Paterno M, Capobianchi MR. 2008. Evaluation of an automated extraction system in combination with Affigene CMV Trender for CMV DNA quantitative determination: Comparison with nested PCR and pp65 antigen test. J Virol Methods 151: 61-65.
2. Boeckh M, Boivin G. 1998. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications. Clin Microbiol Rev 11: 533-554.
3. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 88: 4063-4071.
4. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. 2003. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 101: 407-414.
5. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. 2004. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42: 1142-1148.
6. Boeckh M, Ljungman P. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113: 5711-5719.
7. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N, Roy J. 2000. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 38: 4356-4360.
8. Caliendo AM, St George K, Kao SY, Allega J, Tan BH, LaFontaine R, Bui L, Rinaldo CR. 2000. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 38: 2122-2127.
9. Caliendo AM, Ingersoll J, Fox-Canale AM, Pargman S, Bythwood T, Hayden MK, Bremer JW, Lurain NS. 2007. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol 45: 1723-1727.
10. Cuzick J. 1985. A Wilcoxon-type test for trend. Stat Med 4: 87-90.
11. Deback C, Fillet AM, Dhedin N, Barrou B, Varnous S, Najioullah F, Bricaire F, Agut H. 2007. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. J Clin Virol 40: 173-179.
12. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, Wagner S, Muller CA. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86: 2815-2820.
13. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. 1999. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 190: 177-182.
14. Gerna G, Zavattoni M, Baldanti F, Sarasini A, Chezzi L, Grossi P, Revello MG. 1998. Human cytomegalovirus (HCMV) leukodnaemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 65: 1378-1385.
15. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. 2008. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41: 873-879.
16. Ghaffari SH, Obeidi N, Dehghan M, Alimoghaddam K, Gharehbaghian A, Ghavamzadeh A. 2008. Monitoring of cytomegalovirus reactivation in bone marrow transplant recipients by real-time PCR. Pathol Oncol Res 14: 399-409.
17. Gimeno C, Solano C, Latorre JC, Hernandez-Boluda JC, Clari MA, Remigia MJ, Furio S, Calabuig M, Tormo N, Navarro D. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 46: 3311-3318.
18. Gouarin S, Vabret A, Scieux C, Agbalika F, Cherot J, Mengelle C, Deback C, Petitjean J, Dina J, Freymuth F. 2007. Multicentric evaluation of a new commercial cytomegalovirus real-time PCR quantitation assay. J Virol Methods 146: 147-154.
19. Humar A, Asberg A, Kumar D, Hartmann A, Moussa G, Jardine A, Rollag H, Mouas H, Gahlemann CG, Pescovitz MD. 2009. An assessment of herpesvirus co-infections in patients with CMV disease: Correlation with clinical and virologic outcomes. Am J Transplant 9: 374-381.
20. Kalpoe JS, Kroes AC, de Jong MD, Schinkel J, de Brouwer CS, Beersma MF, Claas EC. 2004. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 42: 1498-1504.
21. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. 1997. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 19: 1111-1116.
22. Ksouri H, Eljed H, Greco A, Lakhal A, Torjman L, Abdelkefi A, Ben Othmen, Ladeb T, Slim S, Zouari A, Abdeladhim B, Ben A, Hassen A. 2007. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation. Transpl Infect Dis 9: 16-21.
23. Lengerke C, Ljubicic T, Meisner C, Loeffler J, Sinzger C, Einsele H, Hebart H. 2006. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 38: 53-60.
24. Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G. 2004. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 73: 412-418.
25. Machida U, Kami M, Fukui T, Kazuyama Y, Kinoshita M, Tanaka Y, Kanda Y, Ogawa S, Honda H, Chiba S, Mitani K, Muto Y, Osumi K, Kimura S, Hirai H. 2000. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol 38: 2536-2542.
26. Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R, Nakazato T, Sato N, Iguchi T, Nagayama H, Takayama N, Hibi T, Ikeda Y. 2002. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 29: 777-782.
27. Pajand O, Ziyaeyan M, Mousavi S, Fatolahzadeh B, Hojabri Z, Bahador A, Abdossamadi Z. 2008. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Exp Clin Transplant 6: 149-154.
28. Pumannova M, Roubalova K, Vitek A, Sajdova J. 2006. Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation. Diagn Microbiol Infect Dis 54: 115-120.
29. Razonable RR, Emery VC. 2004. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 11: 77-86.
30. Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, Smith TF, Paya CV. 2002. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73: 968-973.
31. Solano C, Munoz I, Gutierrez A, Farga A, Prosper F, Garcia-Conde J, Navarro D, Gimeno C. 2001. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 39: 3938-3941.
32. Tang W, Elmore SH, Fan H, Thorne LB, Gulley ML. 2008. Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn Mol Pathol 17: 166-173.
33. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. 2006. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or = 10000copies/ml: A safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 37: 51-56.
34. Von Muller L, Hampl W, Hinz J, Meisel H, Reip A, Engelmann E, Heilbronn R, Gartner B, Kramer O, Einsele H, Hebart H, Ljubicic T, Loffler J, Mertens T. 2002. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 40: 2285-2287.
35. Weinberg A, Schissel D, Giller R. 2002. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 40: 4203-4206.
36. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M. 2002. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: Comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant 29: 599-606.